AbbVie Bid for Biotech Could Expand with Experimental Drug
AbbVie is exploring a cash purchase of about $10.9 billion for a biotech developing an experimental eczema drug, a mo...
Rebalancing can affect how withdrawal rates hold up over time. Learn factors that influence stability and how to adjust portfolio rules.
24,481 articlesAbbVie is exploring a cash purchase of about $10.9 billion for a biotech developing an experimental eczema drug, a mo...
Oil traders weigh the risk of a rush of Iranian crude if sanctions ease, potentially easing inflation but complicatin...
McDonald’s shares fell toward a 52-week low even as quarterly results underscored growing global sales. Investors wei...
Bitcoin has slid to around 60K in six weeks, wiping out years of gains. This piece examines this hidden reason behind...
A 72-year-old widow faced threats that her Social Security could be garnished. The case highlights federal protection...
Strategy pauses bitcoin buys as the firm unveils a $1 billion digital credit repurchase program, boosting cash reserv...
NVIDIA has surged to the top of many investors' lists as AI demand accelerates. This highest-conviction stock right n...
A bold nonprofit initiative pairs BitMine and Sharplink with Joe Lubin to speed Wall Street's entry into Ethereum's o...
A rare, inside look at Kevin Warsh’s thinking on the Fed, told by those closest to him during the crisis and today’s ...
Debt trends are shifting from policy tool to market risk. This report explains how the U.S. rose to financial promine...
Higharc AI has closed a $95 million Series C, backed by USLBM, to accelerate AI-enabled homebuilding. The move aims t...
As July unfolds, investors are eyeing three powerful nuclear energy stocks as policy momentum and grid demand bolster...